EXO+ is focused on developing pharmacological products for the preventive or regenerative treatment of neurons, and therapies for acute and chronic diseases of the central nervous system. The SF500 Investment Committee will finance Exo+, a project led by IBR researchers Claudia Banchio and Hugo Gramajo. The […]